FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Brown

Research Profile

Chemicals & Drugs

Physiology

Living Beings

Anatomy

Disorders

Procedures

Neoplasm Transplantation

Concepts & Ideas

Radiation Dose-Response Relationship

Co-author Network

Publications

TOP 3
J Martin Brown; David J Brenner; David J Carlson
Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer.
Sophia B Chernikova; J Martin Brown
R-loops and genomic instability in Bre1 (RNF20/40)-deficient cells.
J Martin Brown
Imaging tumor sensitivity to a bioreductive prodrug: two for the price of one!

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Brown (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: J Martin Brown; David J Brenner; David J Carlson
Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer.
International journal of radiation oncology, biology, physics 2013;85(5):1159-60.
2012: Sophia B Chernikova; J Martin Brown
R-loops and genomic instability in Bre1 (RNF20/40)-deficient cells.
Cell cycle (Georgetown, Tex.) 2012;11(16):2980-4.
2012: J Martin Brown
Imaging tumor sensitivity to a bioreductive prodrug: two for the price of one!
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(6):1487-9.
2012: Sophia B Chernikova; John C Game; J Martin Brown
Inhibiting homologous recombination for cancer therapy.
Cancer biology & therapy 2012;13(2):61-8.
2011: D Tseng; D A Vasquez-Medrano; J Martin Brown
Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas.
British journal of cancer 2011;104(12):1805-9.
2010: Sophia B Chernikova; Jennifer A Dorth; Olga V Razorenova; John C Game; J Martin Brown
Deficiency in Bre1 impairs homologous recombination repair and cell cycle checkpoint response to radiation damage in mammalian cells.
Radiation research 2010;174(5):558-65.
2010: J Martin Brown; Maximilian Diehn; Billy W Loo
Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.
International journal of radiation oncology, biology, physics 2010;78(2):323-7.
2010: G-One Ahn; Diane Tseng; Cho-Hwa Liao; Mary Jo Dorie; Agnieszka Czechowicz; J Martin Brown
Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(18):8363-8.
2009: Maximilian Diehn; Robert W Cho; Neethan A Lobo; Tomer Kalisky; Mary Jo Dorie; Angela N Kulp; Dalong Qian; Jessica S Lam; Laurie Ailles; Manzhi Wong; Benzion Joshua; Michael J Kaplan; Irene Wapnir; Frederick M Dirbas; George Somlo; Carlos Garberoglio; Benjamin Paz; Jeannie Shen; Sean K Lau; Stephen R Quake; J Martin Brown; Irving L Weissman; Michael F Clarke
Association of reactive oxygen species levels and radioresistance in cancer stem cells.
Nature 2009;458(7239):780-3.
2009: G-One Ahn; J Martin Brown
Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives.
Cell cycle (Georgetown, Tex.) 2009;8(7):970-6.
2009: G-One Ahn; J Martin Brown
Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature.
Angiogenesis 2009;12(2):159-64.
2008: Tatiana Spicakova; Kelly McCann; J Martin Brown
A role for Lsmlp in response to ultraviolet-radiation damage in Saccharomyces cerevisiae.
Radiation research 2008;170(4):411-21.
2008: Shie-Chau Liu; G-One Ahn; Mitomu Kioi; Mary Jo Dorie; Adam Patterson; J Martin Brown
Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.
Cancer research 2008;68(19):7995-8003.
2008: Quynh-Thu Le; Albert C Koong; Yee Yie Lieskovsky; Balasubramanian Narasimhan; Edward Graves; Harlan A Pinto; J Martin Brown; Daniel M Spielman
In vivo 1H magnetic resonance spectroscopy of lactate in patients with stage IV head and neck squamous cell carcinoma.
International journal of radiation oncology, biology, physics 2008;71(4):1151-7.
2008: G-One Ahn; J Martin Brown
Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells.
Cancer cell 2008;13(3):193-205.
2008: James W Evans; Sophia B Chernikova; Lisa A Kachnic; Judit P Banath; Olivier Sordet; Yvette M Delahoussaye; Alejandro Treszezamsky; Brian H Chon; Zhihui Feng; Yongchuan Gu; William Wilson; Yves Pommier; Peggy L Olive; Simon Nicholas Powell; J Martin Brown
Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells.
Cancer research 2008;68(1):257-65.
2007: J Martin Brown
Tumor hypoxia in cancer therapy.
Methods in enzymology 2007;435():297-321.
2006: John C Game; Marsha S Williamson; Tatiana Spicakova; J Martin Brown
The RAD6/BRE1 histone modification pathway in Saccharomyces confers radiation resistance through a RAD51-dependent process that is independent of RAD18.
Genetics 2006;173(4):1951-68.
2006: James A Brown; Gavin Sherlock; Chad L Myers; Nicola M Burrows; Changchun Deng; H Irene Wu; Kelly E McCann; Olga G Troyanskaya; J Martin Brown
Global analysis of gene function in yeast by quantitative phenotypic profiling.
Molecular systems biology 2006;2():2006.0001.
2005: Daniel W Nelson; Hongbin Cao; Yonghua Zhu; Bulbin Sunar-Reeder; Clara Y H Choi; James D Faix; J Martin Brown; Albert C Koong; Amato J Giaccia; Quynh-Thu Le
A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
Cancer research 2005;65(14):6151-8.
2005: Changchun Deng; James A Brown; Dongqing You; J Martin Brown
Multiple endonucleases function to repair covalent topoisomerase I complexes in Saccharomyces cerevisiae.
Genetics 2005;170(2):591-600.
2005: J Martin Brown; Laura D Attardi
The role of apoptosis in cancer development and treatment response.
Nature reviews. Cancer 2005;5(3):231-7.
2004: H Irene Wu; James A Brown; Mary Jo Dorie; Laura Lazzeroni; J Martin Brown
Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C.
Cancer research 2004;64(11):3940-8.
2004: J Martin Brown; William Wilson
Exploiting tumour hypoxia in cancer treatment.
Nature reviews. Cancer 2004;4(6):437-47.
2003: J Martin Brown; George Wilson
Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us?
Cancer biology & therapy 2003;2(5):477-90.
2003: Dirk Vordermark; J Martin Brown
Evaluation of hypoxia-inducible factor-1alpha (HIF-1alpha) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies.
International journal of radiation oncology, biology, physics 2003;56(4):1184-93.
2003: John C Game; Geoff W Birrell; James A Brown; Toru Shibata; Clelia Baccari; Angela M Chu; Marsha S Williamson; J Martin Brown
Use of a genome-wide approach to identify new genes that control resistance of Saccharomyces cerevisiae to ionizing radiation.
Radiation research 2003;160(1):14-24.
2003: Yvette M Delahoussaye; Michael Hay; Frederik Pruijn; William A Denny; J Martin Brown
Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
Biochemical pharmacology 2003;65(11):1807-15.
2003: Quynh-Thu Le; Mary S Kovacs; Mary Jo Dorie; Albert C Koong; David J Terris; Harlan A Pinto; Don R Goffinet; Kent W Nowels; Dan Bloch; J Martin Brown
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.
International journal of radiation oncology, biology, physics 2003;56(2):375-83.
2003: Dirk Vordermark; Douglas R Menke; J Martin Brown
Similar radiation sensitivities of acutely and chronically hypoxic cells in HT 1080 fibrosarcoma xenografts.
Radiation research 2003;159(1):94-101.
2002: Katherine B Peters; J Martin Brown
Tirapazamine: a hypoxia-activated topoisomerase II poison.
Cancer research 2002;62(18):5248-53.
2002: J Martin Brown
Tumor microenvironment and the response to anticancer therapy.
Cancer biology & therapy 2002;1(5):453-8.
2002: Kevin Gang Chen; Norman J Lacayo; George E Durán; Yan Wang; Charles D Bangs; Susan Rea; Mary Kovacs; Athena M Cherry; J Martin Brown; Branimir I Sikic
Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma.
Genes, chromosomes & cancer 2002;34(4):372-83.
2002: Geoff W Birrell; James A Brown; H Irene Wu; Guri Giaever; Angela M Chu; Ronald W Davis; J Martin Brown
Transcriptional response of Saccharomyces cerevisiae to DNA-damaging agents does not identify the genes that protect against these agents.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(13):8778-83.
2002: David J Terris; Edith Y Ho; Hani Z Ibrahim; Mary Jo Dorie; Mary S Kovacs; Quynh-Thu Le; Albert C Koong; Harlan A Pinto; J Martin Brown
Estimating DNA repair by sequential evaluation of head and neck tumor radiation sensitivity using the comet assay.
Archives of otolaryngology--head & neck surgery 2002;128(6):698-702.
2002: J Martin Brown; Dietmar W Siemann
The 93rd Annual Meeting of the American Association for Cancer Research. 6-10 April 2002, San Francisco, California, USA.
Expert opinion on pharmacotherapy 2002;3(5):629-32.
2002: S C Liu; N P Minton; Amato J Giaccia; J Martin Brown
Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.
Gene therapy 2002;9(4):291-6.
2002: Toru Shibata; Amato J Giaccia; J Martin Brown
Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.
Neoplasia (New York, N.Y.) 2002;4(1):40-8.
2001: Dirk Vordermark; T Shibata; J Martin Brown
Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation.
Neoplasia (New York, N.Y.) 2001;3(6):527-34.
2001: Yvette M Delahoussaye; James W Evans; J Martin Brown
Metabolism of tirapazamine by multiple reductases in the nucleus.
Biochemical pharmacology 2001;62(9):1201-9.
2001: Geoff W Birrell; Guri Giaever; Angela M Chu; Ronald W Davis; J Martin Brown
A genome-wide screen in Saccharomyces cerevisiae for genes affecting UV radiation sensitivity.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(22):12608-13.
2001: K B Peters; H Wang; J Martin Brown; G Iliakis
Inhibition of DNA replication by tirapazamine.
Cancer research 2001;61(14):5425-31.
2001: J Martin Brown
Therapeutic targets in radiotherapy.
International journal of radiation oncology, biology, physics 2001;49(2):319-26.
2001: Bradly G Wouters; Yvette M Delahoussaye; James W Evans; G W Birrell; M J Dorie; J Wang; D MacDermed; Roland K Chiu; J Martin Brown
Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine.
Cancer research 2001;61(1):145-52.
2001: Z Goldberg; J Evans; Geoff W Birrell; J Martin Brown
An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
International journal of radiation oncology, biology, physics 2001;49(1):175-82.
2000: J Martin Brown
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
Molecular medicine today 2000;6(4):157-62.
2000: T Shibata; Amato J Giaccia; J Martin Brown
Development of a hypoxia-responsive vector for tumor-specific gene therapy.
Gene therapy 2000;7(6):493-8.
2000: Josh Star-Lack; Elfar Adalsteinsson; MF Adam; David J Terris; Harlan A Pinto; J Martin Brown; Daniel M Spielman
In vivo 1H MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen tension measurements.
AJNR. American journal of neuroradiology 2000;21(1):183-93.
1999: J Martin Brown
The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.
Cancer research 1999;59(23):5863-70.
1999: Mary Jo Dorie; Mary S Kovacs; EC Gabalski; M Adam; Quynh-Thu Le; Daniel A Bloch; Harlan A Pinto; David J Terris; J Martin Brown
DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
Neoplasia (New York, N.Y.) 1999;1(5):461-7.
1999: MF Adam; Mary Jo Dorie; J Martin Brown
Oxygen tension measurements of tumors growing in mice.
International journal of radiation oncology, biology, physics 1999;45(1):171-80.
1999: Mary S Kovacs; D J Hocking; James W Evans; Bronwyn G Siim; Bradly G Wouters; J Martin Brown
Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin.
British journal of cancer 1999;80(8):1245-51.
1999: J Martin Brown; Bradly G Wouters
Apoptosis, p53, and tumor cell sensitivity to anticancer agents.
Cancer research 1999;59(7):1391-9.
1999: MF Adam; EC Gabalski; Daniel A Bloch; John Oehlert; J Martin Brown; A A Elsaid; Harlan A Pinto; David J Terris
Tissue oxygen distribution in head and neck cancer patients.
Head & neck 1999;21(2):146-53.
1999: A el-Said; DR Menke; Mary Jo Dorie; J Martin Brown
Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
Radiation oncology investigations 1999;7(3):163-9.
1998: EC Gabalski; M Adam; Harlan A Pinto; J Martin Brown; Daniel A Bloch; David J Terris
Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers.
The Laryngoscope 1998;108(12):1856-60.
1998: AB Kelson; J P McNamara; A Pandey; K J Ryan; Mary Jo Dorie; P A McAfee; D R Menke; J Martin Brown; M Tracy
1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity.
Anti-cancer drug design 1998;13(6):575-92.
1998: J Martin Brown; L H Wang
Tirapazamine: laboratory data relevant to clinical activity.
Anti-cancer drug design 1998;13(6):529-39.
1998: J Martin Brown
Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
British journal of cancer 1998;77 Suppl 4():12-4.
1998: James W Evans; K Yudoh; Yvette M Delahoussaye; J Martin Brown
Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes.
Cancer research 1998;58(10):2098-101.
1998: J Martin Brown; Amato J Giaccia
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Cancer research 1998;58(7):1408-16.
1997: Bradly G Wouters; Amato J Giaccia; Nicholas C Denko; J Martin Brown
Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism.
Cancer research 1997;57(21):4703-6.
1997: M J Lemmon; P van Zijl; M E Fox; M L Mauchline; Amato J Giaccia; N P Minton; J Martin Brown
Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment.
Gene therapy 1997;4(8):791-6.
1997: J H Elwell; Bronwyn G Siim; James W Evans; J Martin Brown
Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
Biochemical pharmacology 1997;54(2):249-57.
1997: Bronwyn G Siim; DR Menke; Mary Jo Dorie; J Martin Brown
Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
Cancer research 1997;57(14):2922-8.
1997: Bradly G Wouters; J Martin Brown
Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy.
Radiation research 1997;147(5):541-50.
1997: Mary S Kovacs; K Yudoh; James W Evans; DR Menke; J Martin Brown
Stable translocations detected by fluorescence in situ hybridization: a rapid surrogate end point to evaluate the efficacy of a potentiator of tumor response to radiotherapy.
Cancer research 1997;57(4):672-7.
1997: Mary Jo Dorie; J Martin Brown
Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
Cancer chemotherapy and pharmacology 1997;39(4):361-6.
1996: L M Fried; Constantinos Koumenis; SR Peterson; Sherril L Green; P van Zijl; J Allalunis-Turner; David J Chen; R Fishel; Amato J Giaccia; J Martin Brown; C U Kirchgessner
The DNA damage response in DNA-dependent protein kinase-deficient SCID mouse cells: replication protein A hyperphosphorylation and p53 induction.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(24):13825-30.
1996: Bronwyn G Siim; Peter C M van Zijl; J Martin Brown
Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
British journal of cancer 1996;73(8):952-60.
1996: James W Evans; X F Liu; C U Kirchgessner; J Martin Brown
Induction and repair of chromosome aberrations in scid cells measured by premature chromosome condensation.
Radiation research 1996;145(1):39-46.
1995: C U Kirchgessner; C K Patil; James W Evans; C A Cuomo; L M Fried; T Carter; M A Oettinger; J Martin Brown
DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect.
Science (New York, N.Y.) 1995;267(5201):1178-83.
1994: K Sasai; James W Evans; Mary S Kovacs; J Martin Brown
Prediction of human cell radiosensitivity: comparison of clonogenic assay with chromosome aberrations scored using premature chromosome condensation with fluorescence in situ hybridization.
International journal of radiation oncology, biology, physics 1994;30(5):1127-32.
1994: K Sasai; J Martin Brown
Discrepancies between measured changes of radiobiological hypoxic fraction and oxygen tension monitoring using two assay systems.
International journal of radiation oncology, biology, physics 1994;30(2):355-61.
1994: I H Kim; J Martin Brown
Reoxygenation and rehypoxiation in the SCCVII mouse tumor.
International journal of radiation oncology, biology, physics 1994;29(3):493-7.
1994: Joe Gray; D Pinkel; J Martin Brown
Fluorescence in situ hybridization in cancer and radiation biology.
Radiation research 1994;137(3):275-89.
1994: A C Koong; E Y Chen; A S Lee; J Martin Brown; Amato J Giaccia
Increased cytotoxicity of chronic hypoxic cells by molecular inhibition of GRP78 induction.
International journal of radiation oncology, biology, physics 1994;28(3):661-6.
1994: Mary Jo Dorie; D Menke; J Martin Brown
Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
International journal of radiation oncology, biology, physics 1994;28(1):145-50.
1994: Mary S Kovacs; James W Evans; I M Johnstone; J Martin Brown
Radiation-induced damage, repair and exchange formation in different chromosomes of human fibroblasts determined by fluorescence in situ hybridization.
Radiation research 1994;137(1):34-43.
1994: J Martin Brown; A J Giaccia
Tumour hypoxia: the picture has changed in the 1990s.
International journal of radiation biology 1994;65(1):95-102.
1993: C U Kirchgessner; L M Tosto; K A Biedermann; M Kovacs; D Araujo; E J Stanbridge; J Martin Brown
Complementation of the radiosensitive phenotype in severe combined immunodeficient mice by human chromosome 8.
Cancer research 1993;53(24):6011-6.
1993: Mary Jo Dorie; J Martin Brown
Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
Cancer research 1993;53(19):4633-6.
1993: J Martin Brown; Mary S Kovacs
Visualization of nonreciprocal chromosome exchanges in irradiated human fibroblasts by fluorescence in situ hybridization.
Radiation research 1993;136(1):71-6.
1993: I H Kim; M J Lemmon; J Martin Brown
The influence of irradiation of the tumor bed on tumor hypoxia: measurements by radiation response, oxygen electrodes, and nitroimidazole binding.
Radiation research 1993;135(3):411-7.
1993: L Alvarez; James W Evans; R Wilks; J N Lucas; J Martin Brown; Amato J Giaccia
Chromosomal radiosensitivity at intrachromosomal telomeric sites.
Genes, chromosomes & cancer 1993;8(1):8-14.
1993: J Martin Brown
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
British journal of cancer 1993;67(6):1163-70.
1993: C Chang; K A Biedermann; M Mezzina; J Martin Brown
Characterization of the DNA double strand break repair defect in scid mice.
Cancer research 1993;53(6):1244-8.
1993: J R Sun; J Martin Brown
Lack of differential radiosensitization of hypoxic cells in a mouse tumor at low radiation doses per fraction by cisplatin.
Radiation research 1993;133(2):252-6.
1993: J Wang; K A Biedermann; C R Wolf; J Martin Brown
Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
British journal of cancer 1993;67(2):321-5.
1993: J F Spiegel; M A Spear; J Martin Brown
Toxicology of daily administration to mice of the radiation potentiator SR 4233 (WIN 59075).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1993;26(1):79-81.
1993: J Martin Brown; James W Evans; Mary S Kovacs
Mechanism of chromosome exchange formation in human fibroblasts: insights from "chromosome painting".
Environmental and molecular mutagenesis 1993;22(4):218-24.
1992: J Wang; K A Biedermann; J Martin Brown
Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation.
Cancer research 1992;52(16):4473-7.
1992: Amato J Giaccia; J Schwartz; J Shieh; J Martin Brown
The use of asymmetric-field inversion gel electrophoresis to predict tumor cell radiosensitivity.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1992;24(4):231-8.
1992: J Martin Brown
Carbogen and nicotinamide: expectations too high?
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1992;24(2):75-6.
1992: Amato J Giaccia; E A Auger; A Koong; David J Terris; A I Minchinton; G M Hahn; J Martin Brown
Activation of the heat shock transcription factor by hypoxia in normal and tumor cell lines in vivo and in vitro.
International journal of radiation oncology, biology, physics 1992;23(4):891-7.
1992: A Cholon; Amato J Giaccia; A D Lewis; I Hickson; J Martin Brown
What role do glutathione S-transferases play in the cellular response to ionizing radiation?
International journal of radiation oncology, biology, physics 1992;22(4):759-63.
1992: A I Minchinton; M J Lemmon; M Tracy; D J Pollart; A P Martinez; L M Tosto; J Martin Brown
Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
International journal of radiation oncology, biology, physics 1992;22(4):701-5.
1992: Amato J Giaccia; K A Biedermann; L M Tosto; A I Minchinton; Mary S Kovacs; J Martin Brown
Characterization of a CHO cell line resistant to killing by the hypoxic cell cytotoxin SR 4233.
International journal of radiation oncology, biology, physics 1992;22(4):681-4.
1992: H B Stone; A I Minchinton; M Lemmon; D Menke; J Martin Brown
Pharmacological modification of tumor blood flow: lack of correlation between alteration of mean arterial blood pressure and changes in tumor perfusion.
International journal of radiation oncology, biology, physics 1992;22(1):79-86.
1992: J Martin Brown; J Evans; Mary S Kovacs
The prediction of human tumor radiosensitivity in situ: an approach using chromosome aberrations detected by fluorescence in situ hybridization.
International journal of radiation oncology, biology, physics 1992;24(2):279-86.
1992: L M Smith; James W Evans; M Mori; J Martin Brown
The frequency of translocations after treatment for Hodgkin's disease.
International journal of radiation oncology, biology, physics 1992;24(4):737-42.
1992: A I Minchinton; J Martin Brown
Improving the effectiveness of the bioreductive antitumor agent SR 4233 by induced hypoxia.
Advances in experimental medicine and biology 1992;317():177-81.
1992: David J Terris; A I Minchinton; E P Dunphy; J Martin Brown
Computerized histographic oxygen tension measurements of murine tumors.
Advances in experimental medicine and biology 1992;317():153-9.
1991: M J Lemmon; J Martin Brown
Hydralazine does not increase hypoxia in tumors growing in preirradiated tissue.
International journal of radiation oncology, biology, physics 1991;21(6):1435-40.
1991: Amato J Giaccia; A D Lewis; Nicholas C Denko; A Cholon; James W Evans; Charles A Waldren; Thomas D Stamato; J Martin Brown
The hypersensitivity of the Chinese hamster ovary variant BL-10 to bleomycin killing is due to a lack of glutathione S-transferase-alpha activity.
Cancer research 1991;51(16):4463-9.
1991: J Martin Brown
Targeting bioreductive drugs to tumours: is it necessary to manipulate blood flow?
International journal of radiation biology 1991;60(1-2):231-6.
1991: Amato J Giaccia; J Shieh; A Cholon; J Martin Brown
Biochemical evidence for two different mechanisms for bleomycin-induced cell killing.
Mutation research 1991;263(2):69-75.
1991: H B Stone; V K Hirst; R Cribbs; Y H Luu; J Martin Brown
A comparison of radiosensitization by etanidazole and pimonidazole in mouse tumors.
International journal of radiation oncology, biology, physics 1991;20(5):987-95.
1991: James W Evans; J A Chang; A J Giaccia; D Pinkel; J Martin Brown
The use of fluorescence in situ hybridisation combined with premature chromosome condensation for the identification of chromosome damage.
British journal of cancer 1991;63(4):517-21.
1991: K A Biedermann; J Wang; R P Graham; J Martin Brown
SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures.
British journal of cancer 1991;63(3):358-62.
1991: J Martin Brown; M J Lemmon
Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
International journal of radiation oncology, biology, physics 1991;20(3):457-61.
1991: J Martin Brown; M J Lemmon; M R Horsman; W W Lee
Structure-activity relationships for tumour radiosensitization by analogues of nicotinamide and benzamide.
International journal of radiation biology 1991;59(3):739-48.
1991: K A Biedermann; J R Sun; Amato J Giaccia; L M Tosto; J Martin Brown
scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(4):1394-7.
1991: J Martin Brown; A Koong
Therapeutic advantage of hypoxic cells in tumors: a theoretical study.
Journal of the National Cancer Institute 1991;83(3):178-85.
1991: J Martin Brown; M J Lemmon
SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1991;20 Suppl 1():151-6.
1991: Elaine Zeman; J Martin Brown
Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications.
International journal of radiation biology 1991;59(1):117-31.
1990: J Martin Brown; M J Lemmon
Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Cancer research 1990;50(24):7745-9.
1990: Amato J Giaccia; James W Evans; J Martin Brown
Use of fluorescent in situ hybridization to detect chromosomal rearrangements in somatic cell hybrids.
Genes, chromosomes & cancer 1990;2(3):248-51.
1990: M R Horsman; P J Wood; D J Chaplin; J Martin Brown; J Overgaard
The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1990;18(1):49-57.
1990: Elaine Zeman; C I Pearson; J Martin Brown
Induction of hypoxia in glass versus Permanox petri dishes.
Radiation research 1990;122(1):72-6.
1990: J Martin Brown
Tumor hypoxia, drug resistance, and metastases.
Journal of the National Cancer Institute 1990;82(5):338-9.
1990: Elaine Zeman; M J Lemmon; J Martin Brown
Aerobic radiosensitization by SR 4233 in vitro and in vivo.
International journal of radiation oncology, biology, physics 1990;18(1):125-32.
1989: K A Biedermann; J Martin Brown
Comparison between X-rays and SR 4233 for cytotoxicity and repair of potentially lethal damage in human cells.
International journal of radiation biology 1989;56(5):813-6.
1989: J R Sun; J Martin Brown
Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma.
Cancer research 1989;49(20):5664-70.
1989: M R Horsman; P J Wood; J Martin Brown
Misonidazole chemosensitization of EMT6 spheroids to melphalan.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1989;15(1):103-14.
1989: Elaine Zeman; M A Baker; M J Lemmon; C I Pearson; J A Adams; J Martin Brown; W W Lee; M Tracy
Structure-activity relationships for benzotriazine di-N-oxides.
International journal of radiation oncology, biology, physics 1989;16(4):977-81.
1989: Elaine Zeman; J Martin Brown
Pre- and post-irradiation radiosensitization by SR 4233.
International journal of radiation oncology, biology, physics 1989;16(4):967-71.
1989: J Martin Brown
Keynote address: hypoxic cell radiosensitizers: where next?
International journal of radiation oncology, biology, physics 1989;16(4):987-93.
1989: M R Horsman; D J Chaplin; J Martin Brown
Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation.
Radiation research 1989;118(1):139-50.
1989: A K Costa; M A Baker; J Martin Brown; J R Trudell
In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumor agent.
Cancer research 1989;49(4):925-9.
1988: M A Baker; Elaine Zeman; V K Hirst; J Martin Brown
Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity.
Cancer research 1988;48(21):5947-52.
1988: M R Horsman; J Martin Brown; V K Hirst; M J Lemmon; P J Wood; E P Dunphy; J Overgaard
Mechanism of action of the selective tumor radiosensitizer nicotinamide.
International journal of radiation oncology, biology, physics 1988;15(3):685-90.
1988: Elaine Zeman; V K Hirst; M J Lemmon; J Martin Brown
Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1988;12(3):209-18.
1988: J Martin Brown; E J Hall; D G Hirst; T J Kinsella; M M Kligerman; J B Mitchell; E J Travis; Frederick A Valeriote
Chemical modification of radiation and chemotherapy.
American journal of clinical oncology 1988;11(3):288-303.
1988: M A Baker; Y C Taylor; J Martin Brown
Radiosensitization, thiol oxidation, and inhibition of DNA repair by SR 4077.
Radiation research 1988;113(2):346-55.
1988: Y C Taylor; J Martin Brown
Elevation of intracellular glutathione levels following depletion and its relationship to protection against radiation and alkylating agents.
Pharmacology & therapeutics 1988;39(1-3):293-9.
1987: Y C Taylor; J Martin Brown
Radiosensitization in multifraction schedules. II. Greater sensitization by 2-nitroimidazoles than by oxygen.
Radiation research 1987;112(1):134-45.
1987: Y C Taylor; J Martin Brown
Radiosensitization in multifraction schedules. I. Evidence for an extremely low oxygen enhancement ratio.
Radiation research 1987;112(1):124-33.
1986: M R Horsman; D M Brown; M J Lemmon; J Martin Brown; W W Lee
Preferential tumor radiosensitization by analogs of nicotinamide and benzamide.
International journal of radiation oncology, biology, physics 1986;12(8):1307-10.
1986: Elaine Zeman; J Martin Brown; M J Lemmon; V K Hirst; W W Lee
SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
International journal of radiation oncology, biology, physics 1986;12(7):1239-42.